|
Jul 26
|
If EPS Growth Is Important To You, Royalty Pharma (NASDAQ:RPRX) Presents An Opportunity
|
|
Jul 18
|
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating
|
|
Jul 18
|
Royalty Pharma Declares Third Quarter 2025 Dividend
|
|
Jul 17
|
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
|
|
Jul 16
|
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
|
|
Jun 29
|
Investors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past year
|
|
Jun 27
|
5 Revealing Analyst Questions From Royalty Pharma’s Q1 Earnings Call
|
|
Jun 24
|
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
|
|
Jun 4
|
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
|
|
Jun 2
|
Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock?
|
|
May 8
|
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
|
|
May 8
|
Royalty Pharma Reports First Quarter 2025 Results
|
|
May 7
|
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
|
|
Apr 8
|
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
|
|
Feb 23
|
Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025
|
|
Feb 12
|
Royalty Pharma Announces R&D Funding Collaboration With Biogen
|
|
Feb 12
|
Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...
|
|
Feb 11
|
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
|
|
Feb 11
|
Royalty Pharma Reports Q4 and Full Year 2024 Results
|
|
Feb 10
|
Royalty Pharma Earnings: What To Look For From RPRX
|